Mucopolysaccharidosis II - Pipeline Review, H1 2017

  • ID: 4311884
  • Drug Pipelines
  • 57 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AngioChem Inc
  • ArmaGen Inc
  • Bioasis Technologies Inc
  • Green Cross Corp
  • Inventiva
  • RegenxBio Inc
  • MORE
Mucopolysaccharidosis II - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis II - Pipeline Review, H1 2017, provides an overview of the Mucopolysaccharidosis II (Metabolic Disorders) pipeline landscape.

Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a condition that affects many different parts of the body and occurs almost exclusively in males. Signs and symptoms include claw-like hands, protruding tongue, changing facial features, including thickening of the lips, tongue and nostrils and delayed development. Treatment includes bone marrow transplantation, enzyme therapy and gene therapy.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Mucopolysaccharidosis II - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Mucopolysaccharidosis II (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mucopolysaccharidosis II (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 5, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Mucopolysaccharidosis II (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Mucopolysaccharidosis II (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Mucopolysaccharidosis II (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Mucopolysaccharidosis II (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Mucopolysaccharidosis II (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Mucopolysaccharidosis II (Metabolic Disorders)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Mucopolysaccharidosis II (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Mucopolysaccharidosis II (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AngioChem Inc
  • ArmaGen Inc
  • Bioasis Technologies Inc
  • Green Cross Corp
  • Inventiva
  • RegenxBio Inc
  • MORE
  1. Introduction
  2. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Overview
  3. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Companies Involved in Therapeutics Development
  15. AngioChem Inc
  16. ArmaGen Inc
  17. Bioasis Technologies Inc
  18. Green Cross Corp
  19. Inventiva
  20. JCR Pharmaceuticals Co Ltd
  21. Laboratorios Del Dr Esteve SA
  22. RegenxBio Inc
  23. Sangamo Therapeutics Inc
  24. Shire Plc
  25. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Drug Profiles
  26. AGT-182 - Drug Profile
  27. Product Description
  28. Mechanism Of Action
  29. R&D Progress
  30. DUOC-01 - Drug Profile
  31. Product Description
  32. Mechanism Of Action
  33. R&D Progress
  34. EGT-301 - Drug Profile
  35. Product Description
  36. Mechanism Of Action
  37. R&D Progress
  38. Gene Therapy to Activate Iduronate 2 Sulfatase for Mucopolysaccharidosis II - Drug Profile
  39. Product Description
  40. Mechanism Of Action
  41. R&D Progress
  42. idursulfase - Drug Profile
  43. Product Description
  44. Mechanism Of Action
  45. R&D Progress
  46. idursulfase beta - Drug Profile
  47. Product Description
  48. Mechanism Of Action
  49. R&D Progress
  50. JR-032 - Drug Profile
  51. Product Description
  52. Mechanism Of Action
  53. R&D Progress
  54. JR-141 - Drug Profile
  55. Product Description
  56. Mechanism Of Action
  57. R&D Progress
  58. MTf-I2S - Drug Profile
  59. Product Description
  60. Mechanism Of Action
  61. R&D Progress
  62. MTfp-I2S - Drug Profile
  63. Product Description
  64. Mechanism Of Action
  65. R&D Progress
  66. odiparcil - Drug Profile
  67. Product Description
  68. Mechanism Of Action
  69. R&D Progress
  70. pentosan polysulfate sodium - Drug Profile
  71. Product Description
  72. Mechanism Of Action
  73. R&D Progress
  74. Recombinant Iduronate 2-Sulfatase Replacement for Mucopolysaccharidosis II - Drug Profile
  75. Product Description
  76. Mechanism Of Action
  77. R&D Progress
  78. RGX-121 - Drug Profile
  79. Product Description
  80. Mechanism Of Action
  81. R&D Progress
  82. SB-913 - Drug Profile
  83. Product Description
  84. Mechanism Of Action
  85. R&D Progress
  86. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Dormant Projects
  87. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Discontinued Products
  88. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Product Development Milestones
  89. Featured News & Press Releases
  90. Oct 26, 2016: National Center for Child Health and Development Initiates Phase 1/2 Trial of Green Cross' idursulfase-beta ICV for the Treatment of Hunter Syndrome with Neurocognitive Decline
  91. Sep 13, 2016: REGENXBIO Publishes Data from Ongoing Preclinical Studies of NAV Gene Therapy RGX-121
  92. Jul 05, 2016: REGENXBIO Provides Update On Gene Therapy Development Program RGX-121
  93. Apr 19, 2016: Preclinical Data from REGENXBIO’s RGX-121 Gene Therapy Program to be Presented at the American Society of Gene & Cell Therapy 19th Annual Meeting
  94. Feb 25, 2016: ESTEVE Provides Update On EGT-301 For Hunter Syndrome
  95. Jul 31, 2015: biOasis Announces the Successful Delivery to the CNS of an Enzyme used to Treat Hunter Syndrome
  96. Sep 18, 2014: biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation
  97. Oct 02, 2013: Green Cross Exports Orphan Disease Drug Hunterase to Algeria
  98. Apr 08, 2013: Green Cross Announces Publication Of Clinical Trial Paper On Hunter Syndrome Drug Hunterase In International Scientific Press
  99. Feb 18, 2013: Green Cross Receives FDA Orphan Drug Designation For Hunterase For Treatment Of Hunter Syndrome
  100. Jan 10, 2012: Green Cross Receives Korean Approval For Hunterase
  101. Oct 12, 2011: Green Cross Files Application For Korean Approval Of Hunterase For Treatment Of Hunter Syndrome
  102. Appendix
  103. Methodology
  104. Coverage
  105. Secondary Research
  106. Primary Research
  107. Expert Panel Validation
  108. Contact Us
  109. Disclaimer
List of Tables:
  1. Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Products under Development by Companies, H1
  5. Products under Development by Universities/Institutes, H1
  6. Number of Products by Stage and Target, H1
  7. Number of Products by Stage and Mechanism of Action, H1
  8. Number of Products by Stage and Route of Administration, H1
  9. Number of Products by Stage and Molecule Type, H1
  10. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by AngioChem Inc, H1
  11. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by ArmaGen Inc, H1
  12. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Bioasis Technologies Inc, H1
  13. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Green Cross Corp, H1
  14. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Inventiva, H1
  15. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by JCR Pharmaceuticals Co Ltd, H1
  16. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Laboratorios Del Dr Esteve SA, H1
  17. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by RegenxBio Inc, H1
  18. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Sangamo Therapeutics Inc, H1
  19. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline by Shire Plc, H1
  20. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Dormant Projects, H1
  21. Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Discontinued Products, H1
List of Figures:
  1. Number of Products under Development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Number of Products by Targets, H1
  5. Number of Products by Stage and Targets, H1
  6. Number of Products by Mechanism of Actions, H1
  7. Number of Products by Stage and Mechanism of Actions, H1
  8. Number of Products by Routes of Administration, H1
  9. Number of Products by Stage and Routes of Administration, H1
  10. Number of Products by Molecule Types, H1
  11. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AngioChem Inc
  • ArmaGen Inc
  • Bioasis Technologies Inc
  • Green Cross Corp
  • Inventiva
  • JCR Pharmaceuticals Co Ltd
  • Laboratorios Del Dr Esteve SA
  • RegenxBio Inc
  • Sangamo Therapeutics Inc
  • Shire Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll